Sign In
Buy SLGL
$71.50
-2.23 (-3.02%)
At Close: Jun 03, 2026
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
07:00am, Wednesday, 13'th Mar 2024
An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 N
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
07:00am, Thursday, 30'th Nov 2023
NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatment
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
08:06am, Tuesday, 28'th Nov 2023
NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07:00am, Thursday, 09'th Nov 2023
NESS ZIONA, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatment
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
11:17am, Monday, 30'th Oct 2023
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Wednesday, 30'th Aug 2023
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients wi
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
10:01am, Thursday, 10'th Aug 2023
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26.
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
07:00am, Thursday, 10'th Aug 2023
NESS ZIONA, Israel, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates
09:56am, Friday, 12'th May 2023
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.22.
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
07:00am, Monday, 20'th Mar 2023
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i
7 Biotech Stocks That Could Be the Next Big Thing
11:44am, Wednesday, 15'th Mar 2023
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
09:57am, Friday, 10'th Mar 2023
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022.
The Top 7 Penny Stocks to Invest in for the Long-Term
02:32pm, Thursday, 23'rd Feb 2023
Typically, penny stocks represent pure market wagers appropriate only for hardened gamblers. However, every once in a blue moon, a few ideas pop up in this segment that may be worth a genuine investme
3 Generic Drug Stocks to Watch Amid Inflation Pressures
12:02pm, Wednesday, 07'th Dec 2022
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
08:17am, Thursday, 10'th Nov 2022
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022.
